Non-Alcoholic Fatty Liver Disease Trial, Recruiting NCT03587831 Sponsor: University of Minnesota Condition: Non-Alcoholic Fatty Liver Disease
Back to Non Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Trial, Recruiting

NCT03587831
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 30 and 70 years old.
  • You have been diagnosed with a liver condition called NASH (a type of fatty liver disease) with results above a certain severity level, AND/OR you have Type 2 diabetes or prediabetes with a recent blood sugar test (HbA1c) below 9%, AND/OR your Body Mass Index (BMI) is between 35 and 60.
  • You are willing to be randomly assigned to either treatment group in the study.
  • You have health insurance that covers obesity-related treatments and any complications from obesity surgery.
  • A scan shows that fat is present in your liver at the start of the study.
  • You are able to safely have a liver biopsy (a small sample taken from the liver).
  • You are willing and able to follow the study schedule, including completing an initial preparatory period before the study begins.
  • You are able to speak and understand English.
  • You are willing to sign a consent form agreeing to take part.

Who may not be able to join:

  • You have had a heart attack, stroke, chest pain episode, or heart-related procedure in the past 6 months.
  • You currently have heart failure, ongoing chest pain (angina), or significant problems with blood flow in your legs.
  • You have had a blood clot in the lungs or veins in the past 6 months.
  • You have or have had cancer of any kind (except certain minor skin cancers) unless you have been confirmed cancer-free for at least 5 years.
  • You have significant anemia (low red blood cell levels) or a history of problems with blood clotting.
  • Your blood test shows your kidneys are not working well enough (creatinine above 1.8 mg/dL).
  • Your blood tests show certain liver markers are significantly above the normal range, or your blood clotting time is abnormal (confirm with trial site).
  • You drink more than one alcoholic drink per day (or more than 20 grams of alcohol per day).
  • You have previously had surgery on your stomach, bile duct, pancreas, spleen, or colon.
  • You have had a stomach or small intestine ulcer in the past 6 months.
  • You have had a serious internal abdominal infection in the past (with some exceptions for appendix or bowel issues more than 6 months ago).
  • You have previously had an organ transplant.
  • You have HIV, active tuberculosis, active malaria, chronic hepatitis B or C, liver cirrhosis, or inflammatory bowel disease.
  • You are currently pregnant, breastfeeding, or planning to become pregnant within the next 2 years.
  • You have had a dependency on alcohol, drugs, or opioids (not including nicotine) in the past 5 years.
  • You have an active mental health or psychological condition that might make it hard to follow the study plan.
  • You score 17 or higher on a specific depression questionnaire (called the CES-D) based on a typical week for you.
  • You have any long-term or serious illness that would make it difficult to follow the study requirements.
  • A blood test shows your c-peptide level (a marker related to insulin production) is below 1.0 ng/ml after eating.
  • You have a history of an endoscopy showing inflammation or cell changes in your esophagus (the tube connecting your mouth to your stomach).
  • You have any history of difficulty swallowing.
  • Your liver scarring (fibrosis) score is higher than 3 (confirm with trial site).
  • You are currently taking a medication called Rezdiffra (resmetirom).
  • The study doctors or eligibility committee may also exclude someone based on their individual judgment.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Sayeed Ikramuddin, M.D., M.H.A., University of Minnesota

Phone: 6126727422

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 July 2021
Est. completion
15 September 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Histologic improvements in NAFLD Activity Score (NAS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov